Neurodegeneration – News and Features

BioGenes to provide laboratory facilities and key personnel to develop specific monoclonal antibodies against novel neurochemical dementia biomarkers.

Researchers identify two new chemical compounds that can be used to study and manipulate a cellular pathway involved in cancer and degenerative diseases.

The first trial participants have undergone surgery at multiple institutions and additional subjects are currently being enrolled.

Wellcome Trust is deploying Geneus lab and data management solution for genomics, including integrations to next generation sequencing platforms.

Under this agreement, Apitope has granted exclusive worldwide rights to Merck Serono to develop and commercialize Apitope’s product ATX-MS-1467.

The study shows potential application of antagonist compounds in autoimmune and inflammatory diseases.

The collaboration is extended until December 2011 while expansion of the scope of the collaboration will include antibody discovery in ophthalmology.

Galapagos’ pre-clinical candidate G100192 has demonstrated successful Proof of Concept in animal studies.

New brain cells induced in the heroin damaged brain by transplantation of neural stem cells.

A slow, chronic starvation of the brain as we age appears to be one of the major triggers of a biochemical process that causes some forms of Alzheimer's disease.